Platrid-AP 75/75mg is a thienopyridine antiplatelet drug used in thromboembolic disorders. It is an analogue of ticlopidine and acts by decreasing adenosine diphosphate-mediated platelet aggregation
Platrid-AP 75/75mg is primarily indicated in conditions like Atherosclerosis, Myocardial infarction, Myocardial infarction prophylaxis, Peripheral arterial disease, Prophylaxis for NSAID-associated gastric and duodenal ulcers, Stroke Stroke prophylaxis, Thromboembolic complications, and can also be given in adjunctive therapy as an alternative drug of choice in Angina, Unstable angina
Platrid-AP 75/75mgis contraindicated in conditions like Peptic ulcer Intracranial hemorrhage, Hypersensitivity,
The severe or irreversible adverse effects of Platrid-AP 75/75mg which give rise to further complications include Hepatitis, Oedema. The signs and symptoms that are produced after the acute overdosage of Platrid-AP 75/75mg include Blood dyscrasias. The symptomatic adverse reactions produced by Platrid-AP 75/75mg are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dozziness, Headache, Fatigue, Nausea, Diarrhea, Abdominal pain, Rashes, Skin RashX, Dyspepsia, Depression, Arthralgia, Influenza like syndrome, Chest pain, Gl disturbance, Epistaxis.
Use with caution in patients recieving other drugs that increase risk of bleeding including anticogulants platelets and NSAIDS. It should be used with extreme caution in patients with history of bleeding disorder, or who may be at risk of increased bleeding from trauma, surgery or other pathalogical conditions, and patients with ulcers, liver problems or low blood count. If a patient is to undergo elective surgery and an antiplatelet effect is not desired, clopidrogel should be discontinued 7 days prior to surgery. It is classified as pregnancy category B and should be used with caution during pregnancy or lactation
High Risk Groups
Drug should not be given to Paediatrics, and Pregnant Mothers. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies